+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID06799351

Evaluation of Gut Microbiome Profiles in Adults with Chemotherapy-induced Peripheral Neuropathy Receiving Rectal Ozone Therapy in the Randomized Trial OzoParQT

Led by Bernardino Clavo, MD, PhD · Updated on 2026-09-25

42

Participants Needed

1

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Chemotherapy-induced peripheral neuropathy CIPN is a common and challenging side effect of chemotherapy that can reduce treatment effectiveness and lower patients quality of life. Effective treatments for CIPN are limited, and this study explores the possible benefits of rectal ozone therapy as well as the role of the gut microbiome in CIPN severity and treatment response. The study is an observational analysis linked to a randomized clinical trial called OzoParQT, focusing on adult patients with any tumor type experiencing CIPN-related numbness or tingling. Participants receive standard care for their CIPN symptoms combined with 40 sessions of rectal insufflation of an O3O2 gas mixture over 16 weeks. One group receives ozone therapy with increasing O3 concentrations from 10 to 30 gmL, while the control group receives oxygen only placebo. The study aims to compare gut microbiome profiles between patients who improve symptomatically and those who do not, and between those receiving ozone therapy and placebo. During the 16-week study period, participants provide stool samples for gut microbiome analysis and complete questionnaires assessing neuropathy severity, quality of life, anxiety, depression, and biochemical markers of oxidative stress and inflammation. Researchers measure changes in patient-reported numbness and tingling, neuropathy severity scales, toxicity grades, and quality of life scores from baseline to the end of therapy. The study also monitors biochemical markers and psychological status to better understand the relationship between gut microbiome composition and CIPN.

CONDITIONS

Brief Title

Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).

Research Team

B

Bernardino Clavo, MD, PhD

F

Francisco Rodríguez-Esparragón, BSc, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here